BR112012022059A8 - Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa - Google Patents

Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa

Info

Publication number
BR112012022059A8
BR112012022059A8 BR112012022059A BR112012022059A BR112012022059A8 BR 112012022059 A8 BR112012022059 A8 BR 112012022059A8 BR 112012022059 A BR112012022059 A BR 112012022059A BR 112012022059 A BR112012022059 A BR 112012022059A BR 112012022059 A8 BR112012022059 A8 BR 112012022059A8
Authority
BR
Brazil
Prior art keywords
mucosal
producing
antigen
vaccine
iga
Prior art date
Application number
BR112012022059A
Other languages
English (en)
Other versions
BR112012022059A2 (pt
BR112012022059B1 (pt
Inventor
Kido Hiroshi
Mizuno Dai
Original Assignee
The Univ Of Tokushima
Applied Medical Enzyme Res Institute Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Tokushima, Applied Medical Enzyme Res Institute Corporation filed Critical The Univ Of Tokushima
Publication of BR112012022059A2 publication Critical patent/BR112012022059A2/pt
Publication of BR112012022059A8 publication Critical patent/BR112012022059A8/pt
Publication of BR112012022059B1 publication Critical patent/BR112012022059B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA DE MUCOSA PRODUTORA DE UMA IGA DE MUCOSA ANTÍGENO-ESPECÍFICA E IGG DO SANGUE E MÉTODO PARA PRODUZIR UMA VACINA DE MUCOSA PRODUTORA DE UMA IGA DE MUCOSA ANTÍGENO-ESPECÍFICA E UMA IGG DO SANGUE. Vacina de mucosa produtora de uma IgA de mucosa antígeno específica e IgG do sangue, em níveis capazes de exercer uma indução imune efetiva e um efeito preventivo de infecção, dita vacina sendo compreendendo: (a) um veículo AD consistindo de um peptídeo sintético e um lipídio, sendo que o peptídeo sintético e um lipidío, sendo que o peptídeo sintético consiste de sequências de aminoácidos KnLm, onde n é de 4 a8 e m é de 11 a 20; (b) um polímero carboxivinil; e (c) uma proteína antigênica, em uma quantidade incapaz de produzir uma IgA de mucosa suficiente e IgG de sangue para exercer uma indução imune eficaz e um efeito de prevenção de infecção quando utilizado por si. A vacina de mucosa da invenção tem um anticorpo produzindo a capacidade que é mais potente do que aquelas vacinas de mucosa da técnica anterior, e como resultado, ela pode exercer um efeito excelente mesmo com uma quantidade extremamente pequena de um antígeno.
BR112012022059-4A 2010-03-02 2011-03-01 Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa BR112012022059B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010045205 2010-03-02
JP2010-045205 2010-03-02
PCT/JP2011/054586 WO2011108521A1 (ja) 2010-03-02 2011-03-01 粘膜ワクチン

Publications (3)

Publication Number Publication Date
BR112012022059A2 BR112012022059A2 (pt) 2016-11-01
BR112012022059A8 true BR112012022059A8 (pt) 2018-01-02
BR112012022059B1 BR112012022059B1 (pt) 2021-07-27

Family

ID=44542172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022059-4A BR112012022059B1 (pt) 2010-03-02 2011-03-01 Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa

Country Status (9)

Country Link
US (1) US9540420B2 (pt)
EP (1) EP2543387B1 (pt)
JP (1) JP5804278B2 (pt)
KR (1) KR101751376B1 (pt)
CN (1) CN103002908B (pt)
BR (1) BR112012022059B1 (pt)
CA (1) CA2791661C (pt)
RU (1) RU2570394C2 (pt)
WO (1) WO2011108521A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6085886B2 (ja) * 2011-08-29 2017-03-01 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
JP6629877B2 (ja) * 2015-10-30 2020-01-15 帝人ファーマ株式会社 鼻粘膜投与用医薬組成物
CN110548136A (zh) * 2018-05-30 2019-12-10 王美亮 汉坦病毒长肽疫苗
KR20200015323A (ko) 2018-08-03 2020-02-12 에릭스바이오(주) 바이러스 치료 장치 또는 백신 제조 장치
WO2020045155A1 (ja) 2018-08-30 2020-03-05 国立大学法人徳島大学 免疫寛容誘導剤及びアレルギー性疾患の治療又は予防剤
WO2021206103A1 (ja) * 2020-04-06 2021-10-14 応用酵素医学研究所株式会社 皮下投与型ワクチン
CN114681586A (zh) * 2020-12-25 2022-07-01 黑龙江省儒中医疗科技有限公司 一种流感外用疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2001017556A1 (fr) * 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
ES2401425T3 (es) * 2001-10-25 2013-04-19 Medical Research Council Moléculas
US8211442B2 (en) * 2005-08-05 2012-07-03 The University Of Tokushima Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
EP2281574B1 (en) * 2008-04-02 2014-07-09 The University of Tokushima Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same

Also Published As

Publication number Publication date
US20130045232A1 (en) 2013-02-21
EP2543387A4 (en) 2013-06-19
JPWO2011108521A1 (ja) 2013-06-27
CN103002908A (zh) 2013-03-27
EP2543387A1 (en) 2013-01-09
KR101751376B1 (ko) 2017-07-11
BR112012022059A2 (pt) 2016-11-01
CA2791661A1 (en) 2011-09-09
CA2791661C (en) 2019-05-07
JP5804278B2 (ja) 2015-11-04
CN103002908B (zh) 2015-09-02
US9540420B2 (en) 2017-01-10
WO2011108521A1 (ja) 2011-09-09
EP2543387B1 (en) 2016-10-26
RU2570394C2 (ru) 2015-12-10
BR112012022059B1 (pt) 2021-07-27
RU2012140064A (ru) 2014-04-10
KR20130044204A (ko) 2013-05-02

Similar Documents

Publication Publication Date Title
Lavelle et al. Mucosal vaccines—fortifying the frontiers
BR112012022059A8 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
BR112022019781A2 (pt) Vacina para o coronavírus
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
Riedl et al. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
Li et al. Correlates of protection against influenza infection in humans—on the path to a universal vaccine?
EA200900024A1 (ru) Противогриппозная вакцина
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
BR112012018947B8 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
AR083295A1 (es) Metodo para activar celulas t auxiliares
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
Kusakabe et al. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection
BR112016015422A2 (pt) formulações de vacina de frasco único
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
Keijzer et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
Islam et al. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination
WO2011151723A3 (en) Concentration of influenza vaccine antigens without lyophilization
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: APPLIED MEDICAL ENZYME RESEARCH INSTITUTE CORPORAT

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.